CDK4 and ovarian cancer: Another promising combination is the PARP inhibitor, olaparib, with the cyclin-dependent kinases 4/6 (CDK4/6) inhibitor, palbociclib, which had synergistic effects against MYC-overexpressing ovarian cancer cells.